The FDA Must Decide Whether Crispr’s Gene-Editing Promise Is Worth the Risk

FDA Warns of Infection Risk From 26 Big-Brand Eye Drops

Tech firms cite risk to end-to-end encryption as Online Safety Bill gets royal assent

Gene-Editing Trial on Three Individuals for HIV Cure Yields Uncertain Result